通过TNF-α信号通路,SGLT2抑制剂可能会通过TNF-α信号通路预防与代谢综合征相关的心房动:生物信息学研究
Ardian Rizal1,2, Mohammad Saifur Rohman1,2, Adhika Prastya2
1Doctoral Program in Medical Science, Faculty of Medicine Universitas Brawijaya Malang East, Java Indonesia.
Journal of arrhythmia
|October 13, 2025
概括
-葡萄糖共载体2 (SGLT2) 抑制剂可以通过向TNF-α信号通路来降低代谢综合征 (MetS) 中心房动 (AF) 的风险. 这项生物信息学研究确定了参与AF病变发生的关键分子标.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 生物信息学是一种生物信息学.
背景情况:
- 代谢综合征 (MetS) 增加了心房动 (AF) 的风险.
- -葡萄糖共载体2 (SGLT2) 抑制剂显示出降低AF风险的潜力.
- 在与MetS相关的AF中SGLT2抑制剂的机制尚未完全理解.
研究的目的:
- 阐明SGLT2抑制剂在预防MetS中AF中的机制.
- 确定SGLT2抑制剂影响的分子标和途径,用于与MetS相关的AF.
主要方法:
- 使用了网络药理学和生物信息分析.
- 他们使用了公共数据库 (SwissTarget,GeneCards,OMIM,STRING).
- 进行了蛋白质-蛋白质相互作用 (PPI) 网络,基因本体学 (GO) 和KEGG通路分析.
主要成果:
- 在SGLT2抑制剂和MetS相关的AF之间确定了52个共同的目标.
- 作为关键机制,突出显示了TNF-α和AGE-RAGE信号通路.
- 在TNF-α通路中的p38和JNK被确定为减少心房重塑和纤维化的主要目标.
结论:
- SGLT2 抑制剂可以通过 TNF-α 信号通路缓解 MetS 中的 AF.
- 准TNF-α信号传输为与MTS相关的AF提供了潜在的治疗策略.
- 需要进一步的实验验证,以证实这些发现.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
587
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
587
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
583
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
583
01:26Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
01:24Glucagon-like Receptor Agonists
841
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
841